Cargando…

SUN-201 Adrenal Insufficiency After Treatment for Vaping Associated Pulmonary Injury

Background: In 2019 a record number of patients were admitted to our children’s hospital with e-cigarette or vaping-associated lung injury (EVALI). The majority of patients were treated with high-dose prednisone therapy including 3 days of 1000 mg daily followed by a 4 week wean. Because of the conc...

Descripción completa

Detalles Bibliográficos
Autores principales: Pierce, Melinda, Griffiths, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207790/
http://dx.doi.org/10.1210/jendso/bvaa046.1062
_version_ 1783530687577456640
author Pierce, Melinda
Griffiths, Anne
author_facet Pierce, Melinda
Griffiths, Anne
author_sort Pierce, Melinda
collection PubMed
description Background: In 2019 a record number of patients were admitted to our children’s hospital with e-cigarette or vaping-associated lung injury (EVALI). The majority of patients were treated with high-dose prednisone therapy including 3 days of 1000 mg daily followed by a 4 week wean. Because of the concern for iatrogenic adrenal insufficiency, all patients were then placed on a 3-4 weak hydrocortisone taper followed by ACTH stimulation testing. The purpose of this study is to document the incidence of iatrogenic adrenal insufficiency following a 2 months glucocorticoid wean. Methods: All patients seen by the Pulmonary team for EVALI who also received high dose prednisone therapy were referred to Pediatric Endocrinology for ACTH testing. A low dose (1 mcg) ACTH stimulation test was performed with cortisol measurements at baseline, 30 minutes, and 60 minutes. A passing result was any cortisol over 18 ug/dl. Results: An anticipated 20-25 patients will have had ACTH stimulation testing by the time of abstract presentation. Of those that have already completed testing, three of four patients failed the first time. Discussion: High-dose prednisone therapy for EVALI is associated with significant rates of iatrogenic adrenal insufficiency, even after slow hydrocortisone wean. Structures need to be implemented to teach patients about adrenal insufficiency prior to hospital discharge and organize adequate post-discharge follow-up until HPA function returns.
format Online
Article
Text
id pubmed-7207790
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72077902020-05-13 SUN-201 Adrenal Insufficiency After Treatment for Vaping Associated Pulmonary Injury Pierce, Melinda Griffiths, Anne J Endocr Soc Adrenal Background: In 2019 a record number of patients were admitted to our children’s hospital with e-cigarette or vaping-associated lung injury (EVALI). The majority of patients were treated with high-dose prednisone therapy including 3 days of 1000 mg daily followed by a 4 week wean. Because of the concern for iatrogenic adrenal insufficiency, all patients were then placed on a 3-4 weak hydrocortisone taper followed by ACTH stimulation testing. The purpose of this study is to document the incidence of iatrogenic adrenal insufficiency following a 2 months glucocorticoid wean. Methods: All patients seen by the Pulmonary team for EVALI who also received high dose prednisone therapy were referred to Pediatric Endocrinology for ACTH testing. A low dose (1 mcg) ACTH stimulation test was performed with cortisol measurements at baseline, 30 minutes, and 60 minutes. A passing result was any cortisol over 18 ug/dl. Results: An anticipated 20-25 patients will have had ACTH stimulation testing by the time of abstract presentation. Of those that have already completed testing, three of four patients failed the first time. Discussion: High-dose prednisone therapy for EVALI is associated with significant rates of iatrogenic adrenal insufficiency, even after slow hydrocortisone wean. Structures need to be implemented to teach patients about adrenal insufficiency prior to hospital discharge and organize adequate post-discharge follow-up until HPA function returns. Oxford University Press 2020-05-08 /pmc/articles/PMC7207790/ http://dx.doi.org/10.1210/jendso/bvaa046.1062 Text en © Endocrine Society 2020. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Adrenal
Pierce, Melinda
Griffiths, Anne
SUN-201 Adrenal Insufficiency After Treatment for Vaping Associated Pulmonary Injury
title SUN-201 Adrenal Insufficiency After Treatment for Vaping Associated Pulmonary Injury
title_full SUN-201 Adrenal Insufficiency After Treatment for Vaping Associated Pulmonary Injury
title_fullStr SUN-201 Adrenal Insufficiency After Treatment for Vaping Associated Pulmonary Injury
title_full_unstemmed SUN-201 Adrenal Insufficiency After Treatment for Vaping Associated Pulmonary Injury
title_short SUN-201 Adrenal Insufficiency After Treatment for Vaping Associated Pulmonary Injury
title_sort sun-201 adrenal insufficiency after treatment for vaping associated pulmonary injury
topic Adrenal
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207790/
http://dx.doi.org/10.1210/jendso/bvaa046.1062
work_keys_str_mv AT piercemelinda sun201adrenalinsufficiencyaftertreatmentforvapingassociatedpulmonaryinjury
AT griffithsanne sun201adrenalinsufficiencyaftertreatmentforvapingassociatedpulmonaryinjury